Literature DB >> 25390549

The core mechanism of dry eye disease is inflammation.

Yi Wei1, Penny A Asbell.   

Abstract

PURPOSE: The purpose of this article is to review the evidence for the hypothesis that the core mechanism of dry eye disease (DED) is inflammation, including evidence from recent basic, clinical, and translational research involving human patients, animal models, and cell cultures.
METHODS: Using the key words "dry eye + inflammation," the authors conducted a comprehensive search of the PubMed and Web of Science databases for scientific articles published in English between January 1, 1900 and August 30, 2013 on the role of inflammation in DED in cell cultures, animal models, and humans. The resulting articles were then categorized and reviewed.
RESULTS: The literature search revealed a total of 458 publications, almost all published after 1992. The percentages of original studies and review articles are 77.29% (354) and 22.71% (104), respectively. Among the original studies, the number of reports on human DED is 200 (43.7%), on animal models is 115 (25.1%), and cell cultures is 39 (8.5%). A yearly distributing plot revealed that 76% were published from 2003 to 2011, 53% from 2008 to 2012, and 11% during the first 9 months of 2013. This distribution signifies a rapidly growing awareness of the importance of inflammation in DED pathogenesis.
CONCLUSIONS: Inflammation plays a key role in the pathogenesis of DED as evidenced by research using tissue culture, animal models, and subjects with DED. Developing biomarkers for inflammation of the ocular surface will provide improved understanding of the mechanisms leading to DED, classification of the severity of DED, and objective metrics for outcome measures of treatment. The chronicity of the disease suggests that dysregulation of immune mechanisms leads to a cycle of continued inflammation, accompanied by alterations in both innate and adaptive immune responses. Given the underlying mechanism for DED, developing effective and safe anti-inflammatory treatments is likely to be beneficial for patients with DED.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25390549      PMCID: PMC4231828          DOI: 10.1097/ICL.0000000000000042

Source DB:  PubMed          Journal:  Eye Contact Lens        ISSN: 1542-2321            Impact factor:   2.018


  80 in total

1.  Spontaneous T cell mediated keratoconjunctivitis in Aire-deficient mice.

Authors:  S Yeh; C S de Paiva; C S Hwang; K Trinca; A Lingappan; J K Rafati; W J Farley; D-Q Li; S C Pflugfelder
Journal:  Br J Ophthalmol       Date:  2009-05-07       Impact factor: 4.638

Review 2.  Immunoregulation on the ocular surface: 2nd Cullen Symposium.

Authors:  Stephen C Pflugfelder; Michael E Stern
Journal:  Ocul Surf       Date:  2009-04       Impact factor: 5.033

Review 3.  Tearful relations: oxidative stress, inflammation and eye diseases.

Authors:  Tais Hitomi Wakamatsu; Murat Dogru; Kazuo Tsubota
Journal:  Arq Bras Oftalmol       Date:  2008 Nov-Dec       Impact factor: 0.872

4.  Amelioration of murine dry eye disease by topical antagonist to chemokine receptor 2.

Authors:  Sunali Goyal; Sunil K Chauhan; Qiang Zhang; Reza Dana
Journal:  Arch Ophthalmol       Date:  2009-07

5.  Tear cytokine profiles in dysfunctional tear syndrome.

Authors:  Helene Lam; Lauren Bleiden; Cintia S de Paiva; William Farley; Michael E Stern; Stephen C Pflugfelder
Journal:  Am J Ophthalmol       Date:  2008-11-07       Impact factor: 5.258

Review 6.  Rationale for anti-inflammatory therapy in dry eye syndrome.

Authors:  C S de Paiva; S C Pflugfelder
Journal:  Arq Bras Oftalmol       Date:  2008 Nov-Dec       Impact factor: 0.872

7.  Role of Th17 cells in the immunopathogenesis of dry eye disease.

Authors:  S K Chauhan; R Dana
Journal:  Mucosal Immunol       Date:  2009-07       Impact factor: 7.313

8.  sPLA2-IIa is an inflammatory mediator when the ocular surface is compromised.

Authors:  Dongmei Chen; Yi Wei; Xiaohong Li; Seth Epstein; J Mario Wolosin; Penny Asbell
Journal:  Exp Eye Res       Date:  2008-12-16       Impact factor: 3.467

9.  IL-17 disrupts corneal barrier following desiccating stress.

Authors:  C S De Paiva; S Chotikavanich; S B Pangelinan; J D Pitcher; B Fang; X Zheng; P Ma; W J Farley; K F Siemasko; J Y Niederkorn; M E Stern; D-Q Li; S C Pflugfelder
Journal:  Mucosal Immunol       Date:  2009-02-25       Impact factor: 7.313

10.  Characterization of effector T cells in dry eye disease.

Authors:  Jaafar El Annan; Sunil K Chauhan; Tatiana Ecoiffier; Qiang Zhang; Daniel R Saban; Reza Dana
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-04-01       Impact factor: 4.799

View more
  67 in total

1.  Dry Eye Assessment and Management (DREAM©) Study: Study design and baseline characteristics.

Authors:  Penny A Asbell; Maureen G Maguire; Ellen Peskin; Vatinee Y Bunya; Eric J Kuklinski
Journal:  Contemp Clin Trials       Date:  2018-06-06       Impact factor: 2.226

2.  The Dry Eye Assessment and Management (DREAM) extension study - A randomized clinical trial of withdrawal of supplementation with omega-3 fatty acid in patients with dry eye disease.

Authors:  Munira Hussain; Roni M Shtein; Maxwell Pistilli; Maureen G Maguire; Marko Oydanich; Penny A Asbell
Journal:  Ocul Surf       Date:  2019-08-16       Impact factor: 5.033

3.  n-3 Fatty Acid Supplementation for the Treatment of Dry Eye Disease.

Authors:  Penny A Asbell; Maureen G Maguire; Maxwell Pistilli; Gui-shuang Ying; Loretta B Szczotka-Flynn; David R Hardten; Meng C Lin; Roni M Shtein
Journal:  N Engl J Med       Date:  2018-04-13       Impact factor: 91.245

Review 4.  Ocular mucous membrane pemphigoid: a review.

Authors:  Samanta Taurone; Marialuisa Spoletini; Massimo Ralli; Pietro Gobbi; Marco Artico; Laszlò Imre; Cecília Czakò; Illés Kovàcs; Antonio Greco; Alessandra Micera
Journal:  Immunol Res       Date:  2019-06       Impact factor: 2.829

5.  Treg-recruiting microspheres prevent inflammation in a murine model of dry eye disease.

Authors:  Michelle L Ratay; Andrew J Glowacki; Stephen C Balmert; Abhinav P Acharya; Julia Polat; Lawrence P Andrews; Morgan V Fedorchak; Joel S Schuman; Dario A A Vignali; Steven R Little
Journal:  J Control Release       Date:  2017-05-10       Impact factor: 9.776

6.  The Key Role of VEGF in the Cross Talk between Pterygium and Dry Eye and Its Clinical Significance.

Authors:  Chang Liu; Yiyue Song; Xiaoran Wang; Zhaoguang Lai; Chaoyang Li; Pengxia Wan; Nuo Xu; Danping Huang; Yizhi Liu; Zhichong Wang
Journal:  Ophthalmic Res       Date:  2020-01-10       Impact factor: 2.892

Review 7.  Modern Therapeutic Approaches for Noninfectious Ocular Diseases Involving Inflammation.

Authors:  Michelle L Ratay; Elena Bellotti; Riccardo Gottardi; Steven R Little
Journal:  Adv Healthc Mater       Date:  2017-10-16       Impact factor: 9.933

8.  Comparative lipidomic analysis of inflammatory mediators in the aqueous humor and tear fluid of humans and rabbits.

Authors:  Dmitry V Chistyakov; Nadezhda V Azbukina; Alina A Astakhova; Sergei V Goriainov; Viktor V Chistyakov; Veronika V Tiulina; Viktoriia E Baksheeva; Vladislav I Kotelin; Elena V Fedoseeva; Andrey A Zamyatnin; Pavel P Philippov; Olga A Kiseleva; Alexander M Bessmertny; Ivan I Senin; Elena N Iomdina; Marina G Sergeeva; Evgeni Yu Zernii
Journal:  Metabolomics       Date:  2020-02-12       Impact factor: 4.290

9.  Effect of trapping vascular endothelial growth factor-A in a murine model of dry eye with inflammatory neovascularization.

Authors:  Jin Woo Kwon; Jin A Choi; Eun Young Shin; Tae Yoon La; Dong Hyun Jee; Yeon Woong Chung; Yang Kyung Cho
Journal:  Int J Ophthalmol       Date:  2016-11-18       Impact factor: 1.779

10.  Amniotic membrane extract eye drops for ocular surface diseases: use and clinical outcome in real-world practice.

Authors:  Noelia Sabater-Cruz; Marc Figueras-Roca; Miriam Ferrán-Fuertes; Elba Agustí; Eva M Martínez-Conesa; María Luisa Pérez-Rodríguez; Anna Vilarrodona; Ricardo P Casaroli-Marano
Journal:  Int Ophthalmol       Date:  2021-04-17       Impact factor: 2.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.